Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 02:06:18 06/03/2026 pm IST			5-day change	1st Jan Change
77.51 ^EUR	-0.28%		-5.69%	-6.29%

05/03	Merck Outlook Disappoints – MS Drug Patent Loss Weighs on Forecast	RE
05/03	Germany's Merck KGaA Expects Currency Headwinds to Weigh on Earnings	DJ

SANOFI : Barclays keeps its Buy rating

Published on 07/02/2025 at 04:15 pm IST

MarketScreener with dpa-AFX Analyser

SANOFI

-0.28%

Emily Field from Barclays retains his positive opinion on the stock with a Buy rating. The target price is reduced from EUR 125 to EUR 115.

Latest news about Sanofi

05/03	Merck Outlook Disappoints – MS Drug Patent Loss Weighs on Forecast	RE
05/03	Germany's Merck KGaA Expects Currency Headwinds to Weigh on Earnings	DJ
04/03	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
04/03	Euroapi
04/03	Antengene, Sino Biopharmaceutical Shares Jump After New Drug Licensing Deals	DJ
04/03	Sino Biopharm Unit Signs Global License Deal With Sanofi for Rovadicitinib	MT
04/03	Sino Biopharm Inks Up to $1.5 Billion Deal With Sanofi for Cancer Treatment	DJ
04/03	Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion	RE
04/03	Blackstone Gives Teva $400 Million to Develop Inflammatory Bowel Disease Treatment	DJ
04/03	Teva, Blackstone Life Sciences Enter $400 Million Funding Deal to Advance Duvakitug	MT
04/03	Sino Biopharmaceutical discloses exclusive license agreement for rovadicitinib with Sanofi	RE
03/03	Euroapi S.A. Provides Earnings Guidance for the Fy 2026	CI
02/03	European Stocks Drop Sharply in Monday Trading as US Attack on Iran Rattles Investors	MT
02/03	Roche Multiple Sclerosis Drug Meets Main Goal in Late-Stage Trial -- Update	DJ
02/03	Sanofi Says Rilzabrutinib Receives Orphan Drug Status in Japan	MT

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).

Employees

74,846

Sector

Pharmaceuticals

Calendar

23/04 - Earnings release - Q1 2026

More about the company